| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_665a1ccbeb11cc1bcdd3c4d078d4e3f0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-70 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1891 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-39 |
| filingDate |
2008-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12061751fbe554c544fa34bdfa5d61d8 |
| publicationDate |
2009-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20090120356-A |
| titleOfInvention |
Acute Lung Injury Treatment |
| abstract |
The present invention relates to the use of COMP-Ang 1 as a therapeutic agent for acute lung injury, wherein COMP-Ang 1 inhibits inflammatory cell infiltration around the bronchus by reducing the expression of increased cytokines and adhesive substances in a mouse model of acute lung injury. In addition, it has a therapeutic effect that reduces airway hypersensitivity and inhibits increased vascular endothelial cell growth factor (VEGF) and vascular permeability. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112611877-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112611877-B |
| priorityDate |
2008-05-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |